Drug Discovery World

FEBRUARY 8, 2024

In 2023, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. This all creates numerous challenges for the market.

Gene Therapy 59

Gene Therapy Gene Bioinformatics Life Science 59

Drug Discovery World

OCTOBER 3, 2023

Earlier this year, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. This all creates numerous challenges for the market.

Gene Therapy 52

Gene Therapy Gene Life Science Bioinformatics 52

pharmaphorum

JANUARY 19, 2022

This will provide researchers with the option to analyse their data without the need to learn code, which can be a challenging requirement for those not au fait with bioinformatics. Research Instruments is the main distributor for genomic and life science research products in the region.

RNA 72

RNA Research Life Science Bioinformatics 72

XTalks

APRIL 21, 2023

The application of whole genome sequencing (WGS) to derive a more complete understanding of cancer has been a central goal of cancer researchers even before the first human genome was decoded in 2003. Ultima Genomics has already partnered with other leading biotech startups.

Genome 97

Genome Genomics Bioinformatics Genetics 97

Drug Discovery World

JULY 11, 2023

Tim Lowery , President, JSR Life Sciences, asks whether artificial intelligence can do for life sciences what it has done in other sectors and whether these tools can keep up with the complexities of human biology. So, where do we go from here to realise their potential in life sciences?

Big Data 40

Big Data Development Life Science Drugs 40

Roots Analysis

AUGUST 28, 2022

The up-and-coming field of spatial genomics in biology promises to bridge the gap between high plex, high throughput, and high resolution. 70+ spatial Genomics solutions are developed by industry and non-industry players. 70+ spatial Genomics solutions are developed by industry and non-industry players. Concluding Remarks.

Genome 52

Genome Genomics RNA Genome Project 52

XTalks

NOVEMBER 7, 2022

These tumor-derived entities are used to derive genomic and proteomic data. Detection of Genomic Alterations from cfDNA: Targeted, Non-Personalized Approaches. Detection of Genomic Alterations from cfDNA: Personalized, Targeted Assays. Optimal methods for bioinformatic analysis are still needed.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98